Arbutus Biopharma (NASDAQ:ABUS) Lowered to Sell at ValuEngine

Arbutus Biopharma (NASDAQ:ABUS) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday, May 1st, ValuEngine reports.

Several other equities analysts have also commented on the stock. Echelon Wealth Partners reiterated a “hold” rating on shares of Arbutus Biopharma in a research note on Monday, March 11th. Zacks Investment Research raised Arbutus Biopharma from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a report on Tuesday, March 12th. Chardan Capital reissued a “buy” rating and issued a $6.50 price objective on shares of Arbutus Biopharma in a report on Sunday, March 10th. Finally, BidaskClub raised Arbutus Biopharma from a “hold” rating to a “buy” rating in a report on Tuesday, March 5th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. Arbutus Biopharma currently has a consensus rating of “Hold” and a consensus target price of $6.25.

ABUS stock opened at $2.40 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 12.75 and a current ratio of 12.75. Arbutus Biopharma has a fifty-two week low of $2.18 and a fifty-two week high of $12.60. The company has a market cap of $136.44 million, a P/E ratio of -2.35 and a beta of 1.61.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.47) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.16). The company had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $1.18 million. Arbutus Biopharma had a negative net margin of 1,237.92% and a negative return on equity of 95.26%. Analysts anticipate that Arbutus Biopharma will post -1.32 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc lifted its holdings in shares of Arbutus Biopharma by 15.8% during the fourth quarter. Legal & General Group Plc now owns 28,407 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 3,867 shares during the period. DekaBank Deutsche Girozentrale lifted its holdings in shares of Arbutus Biopharma by 21.1% during the first quarter. DekaBank Deutsche Girozentrale now owns 34,500 shares of the biopharmaceutical company’s stock worth $311,000 after purchasing an additional 6,000 shares during the period. Alps Advisors Inc. lifted its holdings in shares of Arbutus Biopharma by 4.7% during the first quarter. Alps Advisors Inc. now owns 134,053 shares of the biopharmaceutical company’s stock worth $480,000 after purchasing an additional 6,016 shares during the period. BNP Paribas Arbitrage SA acquired a new stake in shares of Arbutus Biopharma during the first quarter worth $26,000. Finally, Teachers Advisors LLC lifted its holdings in shares of Arbutus Biopharma by 12.5% during the third quarter. Teachers Advisors LLC now owns 75,945 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 8,428 shares during the period. 43.96% of the stock is owned by hedge funds and other institutional investors.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

See Also: Trading Penny Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.